Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) have been revealed, and have not disappointed.
Welcome to your gateway to the IMF's global economic data. Our new data portal provides streamlined access to timely, reliable, and easy-to-understand macroeconomic and financial data. While the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback